Shareholders approve SKNY acquisition; combined enterprise value >$60M

MIRA PHARMACEUTICALS, INC.

SKNY will contribute $5M in cash or assets to MIRA at closing.
Moore Financial Consulting valued SKNY at $30.5M and MIRA at $30M; combined >$60M.
Directors elected: Erez Aminov, Matthew Whalen, Matthew Del Giudice, Denil Nanji Shekhat, Edward MacPherson.
2022 Omnibus Incentive Plan amended: shares increased from 5M to 8M, option repricing allowed.
Transaction expected to close shortly, subject to customary closing conditions.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.